Health 2.0 Europe: Over 35 Speakers from 15 Countries Already Confirmed

27 - 28 October 2011, Berlin, Germany.
Following the success of our first event in Paris in April 2010, the 2nd annual Health 2.0 Europe to hip Berlin. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offering. The 2nd edition will reconvene all the leaders and stakeholders in web 2.0 for health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

Health investor Esther Dyson to present on 'From Health to Wellness 2.0'
An active investor in technology start-ups with a keen interest in the potential of internet technology to change healthcare, Esther Dyson from EDventure Holdings will present on 'From Health to Wellness 2.0'. Her health technology investments include Medstory, sold to Microsoft in 2007, 23andMe, Habit Labs, Medscape, OrganizedWisdom, PatientsLikeMe and ReliefInsite.

Over 35 speakers already confirmed
Confirmed speakers also include:

  • Roberto ASCIONE, Publicis Healthware International, Italy
  • Alberto SANNA, Fondazione Centro San Raffaele, Italy
  • Gábor GYARMATI, Szinapszis Group, Hungary
  • Anna GYARMATI, KamaszPanasz, Hungary
  • Emma STANTON, Department of Health, UK
  • Chris COOPER, EPG Health Media, UK
  • Matt JAMESON EVANS, HealthUnlocked, UK
  • Tim RINGROSE, Networks in Health/Doctors.net.uk, UK,
  • Howard LAST, Active Medicine Ltd, UK
  • Jonathan BLOOR, DocCom, UK
  • Anatole MENON-JOHANSSON, SXT Health CIC, UK
  • Frank ANTWERPES, DocCheck, Germany
  • Michael ALVERS, Transinsight GmbH, Germany
  • Britta LANG, Cochrane Collaboration, Germany
  • Jorge Juan FERNANDEZ, Hospital Sant Joan de Déu, Spain
  • Frederic LLORDACHS, Doctoralia, Spain
  • Miguel CABRER, Medting, Spain
  • Bartho HENGST, KWF Kankerbestrijding, The Netherlands
  • René SIELHORST, Intenz, The Netherlands
  • Joris MOOLENAAR, IPPZ, The Netherlands
  • Robert HALKES, Drimpy, The Netherlands
  • Jasper TEN DAM, my Jellinek, The Netherlands
  • Marco VITULA, Diagnosia, Austria
  • Stephen COOK, 23 Gears Web Systems, Sweden
  • Anna OMSTEDT LINDGREN, MedUniverse, Sweden
  • Greg BIGGERS, Genomera, US
  • Pablo GRAIVER, TrialReach, UK/Israel
  • Dennis VAN ROOIJ, medCrowd, UK/The Netherlands
  • Laurent COUSSIRAT, The Mood Institute, France
  • Ulrich SCHULZE-ALTHOFF, Medisana Space Technologies GmbH, Germany
  • Roman SCHENK, Protegia GmbH, Germany
  • Rachel IREDALE, Cancer Genetics Story Bank, UK
  • Wouter TUIL, MijnZorgnet, NL
  • Roman RITTWEGER, Advisors in Healthcare
  • David Clifford, PatientsLikeMe, USA
  • Kai Sostmann, Charité University Hospital, Germany
  • Topi Hanhela, Pharmaceutical Information Centre, Finland

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...